Skip to main content

Advertisement

SpringerLink
Log in

Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity

  • Pediatrics
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare laser photocoagulation and intravitreal injection of bevacizumab (IVB) treatment for retinopathy of prematurity (ROP).

Methods

The study included 52 eyes of 26 patients after ROP treatment who were observed up to 5 years of age. Twenty-eight eyes received laser photocoagulation as the initial treatment (laser group), and twenty-four eyes underwent IVB (IVB group). We collected data on gestational age, birth weight, 1- and 5-min Apgar scores, zone and stage at the time of treatment, recurrence of ROP and best-corrected visual acuity (BCVA) (logMAR), equivalent spherical value (SE), ocular complications, and developmental delay at the age of 5.

Results

More zone I low-stage eyes were treated with IVB than laser. There was no difference in BCVA (p = 0.836). Although the mean SE was not different between the groups (p = 0.280), the prevalence of myopia was significantly higher in the laser group (p = 0.020). Developmental delay was observed in 3 of 14 and 3 of 12 cases in the laser and IVB groups, respectively (p = 0.596). Retinal holes were observed in 2 eyes in the IVB group, with 1 developing localized retinal detachment. There were no significant differences between the groups in the other factors.

Conclusions

Compared to laser for ROP, IVB was not inferior in neurodevelopment or visual outcome and was superior in refractive error. As cases in the IVB group showed retinal holes, long-term follow-up with fundus examination is recommended after IVB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hartnett ME, Penn JS (2012) Mechanisms and management of retinopathy of prematurity. N Engl J Med 367:2515–2526

    Article  CAS  Google Scholar 

  2. Hurley BR, McNamara JA, Fineman MS et al (2006) Laser treatment for retinopathy of prematurity: evolution in treatment technique over 15 years. Retina 26:S16–S17

    Article  Google Scholar 

  3. Geloneck MM, Chuang AZ, Clark WL et al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132:1327–1333

    Article  Google Scholar 

  4. McLoone E, O’Keefe M, McLoone S, Lanigan B (2007) Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of Goldmann perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus 44:170–173

    Article  Google Scholar 

  5. Mutlu FM, Sarici SU (2013) Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol 6:228–236

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Chung EJ, Kim JH, Ahn HS, Koh HJ (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:1727–1730

    Article  CAS  Google Scholar 

  7. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603–615

    Article  CAS  Google Scholar 

  8. Mueller B, Salchow DJ, Waffenschmidt E et al (2017) Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol 101:365–370

    CAS  PubMed  Google Scholar 

  9. Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL (2003) Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 163:879–887

    Article  CAS  Google Scholar 

  10. Rosenstein JM, Krum JM, Ruhrberg C (2010) VEGF in the nervous system. Organogenesis 6:107–114

    Article  Google Scholar 

  11. Lepore D, Quinn GE, Molle F et al (2014) Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 121:2212–2219

    Article  Google Scholar 

  12. Morin J, Luu TM, Superstein R et al (2016) Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 137:e20153218

    Article  Google Scholar 

  13. Kennedy KA, Mintz-Hittner HA (2018) Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS 22:61–65.e1

    Article  Google Scholar 

  14. Lien R, Yu MH, Hsu KH et al (2016) Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS One 11:e0148019

    Article  Google Scholar 

  15. International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991–999

    Article  Google Scholar 

  16. Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group (2004) Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 102:233–250

    PubMed  PubMed Central  Google Scholar 

  17. Flitcroft DI, He M, Jonas JB et al (2019) IMI - Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci 60:M20–M30

    Article  Google Scholar 

  18. Kawabe K, Kondo S, Matsumoto M et al (2016) Developmental quotient to estimate intelligence in autism spectrum disorder. Pediatr Int 58:963–966

    Article  Google Scholar 

  19. Koyama T, Osada H, Tsujii H, Kurita H (2009) Utility of the Kyoto Scale of Psychological Development in cognitive assessment of children with pervasive developmental disorders. Psychiatry Clin Neurosci 63:241–243

    Article  Google Scholar 

  20. Shibasaki J, Mukai T, Tsuda K et al (2020) Outcomes related to 10-min Apgar scores of zero in Japan. Arch Dis Child Fetal Neonatal Ed 105:64–68

    Article  Google Scholar 

  21. Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR (2015) Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology 122:1008–1015

    Article  Google Scholar 

  22. Lee YS, See LC, Chang SH et al (2018) Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment. Am J Ophthalmol 192:20–30

    Article  Google Scholar 

  23. Lepore D, Quinn GE, Molle F et al (2018) Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology 125:218–226

    Article  Google Scholar 

  24. Hamad AE, Moinuddin O, Blair MP et al (2020) Late-onset retinal findings and complications in untreated retinopathy of prematurity. Ophthalmol Retina 4:602–612

    Article  Google Scholar 

  25. Yoon JM, Shin DH, Kim SJ et al (2017) Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I. Retina 37:88–96

    Article  CAS  Google Scholar 

  26. Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP (2016) Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina 47:280–283

    Article  Google Scholar 

  27. Gnanaraj L, Brennan R, Cottrell DG (2003) Retinopathy of prematurity in practice II: long-term results following treatment for threshold disease. Eye (Lond) 17:189–193

    Article  CAS  Google Scholar 

  28. Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN (2013) An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol 155:150–158.e1

    Article  CAS  Google Scholar 

  29. Gerber HP, Hillan KJ, Ryan AM et al (1999) VEGF is required for growth and survival in neonatal mice. Development 126:1149–1159

    Article  CAS  Google Scholar 

  30. Walsh MC, Morris BH, Wrage LA et al (2005) Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. J Pediatr 146:798–804

    Article  Google Scholar 

  31. Novitskaya ES, Dahlmann-Noor AH, Adams GGW, Allen LE (2020) Retinopathy of prematurity treatment in the UK: trends in neonatal anaesthetic support and location of treatment from a national surveillance study. Eur J Pediatr. 179:1603–1607

    Article  Google Scholar 

  32. Honda S, Hirabayashi H, Tsukahara Y, Negi A (2008) Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 246:1061–1063

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki, 305-8575, Japan

    Tomoya Murakami, Yoshimi Sugiura, Fumiki Okamoto, Yoshifumi Okamoto, Atsuko Kato, Sujin Hoshi & Tetsuro Oshika

  2. Department of Child Health, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan

    Motomichi Nagafuji & Yayoi Miyazono

Authors
  1. Tomoya Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshimi Sugiura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fumiki Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshifumi Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Atsuko Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sujin Hoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Motomichi Nagafuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yayoi Miyazono
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tetsuro Oshika
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Design of the study (T.M., A.K., M.N., Y.M., and T.O.); conduct of the study (T.M., Y.S., Y.O., and A.K.); data collection (T.M., F.O., S.H., and M.N.); management, analysis, and interpretation of the data (T.M., F.O., S.H., and M.N.); preparation of the manuscript (T.M. and Y.S.); review of the manuscript (F.O. and T.O.); approval of the manuscript (Y.O., A.K., S.H., M.N., and Y.M.,).

Corresponding author

Correspondence to Tomoya Murakami.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murakami, T., Sugiura, Y., Okamoto, F. et al. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 259, 2849–2855 (2021). https://doi.org/10.1007/s00417-021-05137-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-021-05137-9

Keywords

Search

Navigation